Human Monoclonal Antibodies (mAb): Interrogation Of The Memory B Cell Compartment As A Powerful Platform For The Discovery And Development Of Superior Therapeutics | 5411
ISSN: 2157-2526

Journal of Bioterrorism & Biodefense
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Human monoclonal antibodies (mAb): Interrogation of the memory B cell compartment as a powerful platform for the discovery and development of superior therapeutics

International Conference on Biothreats & Biodefense

Aurelio Bonavia

ScientificTracks Abstracts: J Bioterr Biodef

DOI: 10.4172/2157-2526.S1.002

Background: Our High Throughput proprietary I-STARTM (in-situ therapeutic antibody rescue) technology platform enables the discovery of fully human therapeutic antibody candidates eliminating the need for lengthy processes of humanization, affinity maturation and other optimization. The interrogation of the memory B cell compartment allows scanning the repertoire for antibodies in a donor and the identification of antibodies often directed against novel, rare, including conformational epitopes. Using I-STARTM we have successfully identified the first truly broad spectrum anti-influenza virus mAb, TCN-032, and a large number of highly potent, broadly neutralizing antibodies (bNAbs) against HIV. We will present our clinical influenza program illustrating the advantages of I-STARTM. TCN-032 is a first in class drug targeting the M2 protein with a new mechanism of action. This high affinity, high avidity fully human IgG1κ mAb demonstrates nanomolar ADCC and CDC in vitro activity. In vivo, prophylactic and therapeutic efficacy was confirmed in mice with seasonal including highly pathogenic H5N1 strains. The antibody recognizes 98% of all human, avian and swine influenza A strains sequenced to date and has a high barrier to viral escape. Fully human mAbs present a solid approach to defend against biothreat pathogens providing a high safety margin and reasonably faster development times compared to small molecules. Theraclone?s I-STARTM technology can also contribute to vaccine engineering and the development of diagnostics.
Bonavia is currently the head of the Biology group at Theraclone Sciences, developing therapeutic antibodies for infectious diseases. Previously, Dr. Bonavia led antiviral programsfor respiratory syncytial virus, influenza virus, and Ebola virus at Novartis and Functional Genetics. He obtained his Ph.D. in microbiology at the University of Colorado Health Sciences Center and after a postdoctoral trainingin retroviruses at Johns Hopkins Medical Schoolhejoined the laboratory of viral diseases at NIH-NIAID to carry out research on HCoV-SARS. Dr. Bonavia has focused on R&D of small molecules and biologics against respiratory and biodefense viruses with an emphasis on host-targets.